NASDAQ, PDLI - Pdl Biopharma Inc
We are a biopharmaceutical company focused on the discovery and development
of novel antibodies in oncology and immunologic diseases. We receive royalties
and other revenues through licensing agreements with numerous biotechnology and
pharmaceutical companies based on our proprietary antibody humanization
technology platform. These licensing agreements have contributed to the
development by our licensees of nine marketed products. We currently have
several investigational compounds in clinical development for severe or
life-threatening diseases, two of which we are developing in collaboration with
Biogen Idec MA, Inc. (Biogen Idec). We began marketing and selling acute-care
products in the hospital setting in the United States and Canada in March 2005;
however, in August 2007, we began the process of divesting each of our
commercial products and had completely divested these assets as of March 7,
2008.
Our aim is to discover and develop antibody products. ...
Read SEC Filing on NASDAQ.com »